Indication

As monotherapy or in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)

Medicine details

Medicine name:
acalabrutinib (Calquence)
SMC ID:
SMC2347
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
14 June 2021
SMC meeting date:
04 May 2021
Patient group submission deadline:
05 April 2021